VTRS — Viatris Inc.
$18.00-2.60%
Last close: · regular session
Last 60 sessions
VTRS closed at $18.00 (-2.60%) on Oct 23, 2026. Float: 1.1B shares. Latest SEC filing: SC TO-C on Oct 8, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for VTRS in the TickerWise workspace.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ
- Employees: 32,000
- Website: https://www.viatris.com
Latest SEC filings for VTRS
Latest VTRS news
- Viatris, Opus granted FDA label expansion for Ryzumvi in presbyopia Read article
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio Read article
- Viatris to buy Pacira BioSciences for $36.50/share in cash Read article
- Viatris to Buy Pacira BioSciences for $1.65 Billion Read article
- Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Read article
- VTRS vs. AVTR: Which Stock Is the Better Value Option? Read article
- Should Value Investors Buy Viatris (VTRS) Stock? Read article
- Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.